Literature DB >> 19661290

Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

Robert L Giuntoli1, Tonya J Webb, Alessia Zoso, Ophelia Rogers, Teresa P Diaz-Montes, Robert E Bristow, Mathias Oelke.   

Abstract

BACKGROUND: To identify immunosuppressive elements present in ovarian cancer associated ascites. PATIENTS AND METHODS: Ascites and plasma were obtained from ovarian, primary peritoneal or fallopian tube cancer patients. Surface markers were identified by fluorescence-activated cell sorting (FACS). Cytokine and chemokine concentrations were measured with LINCOplex microarrays. Antigen-specific T-lymphocytes from ascites and plasma were expanded with artificial antigen-presenting cells (aAPC). Cell-mediated immune response was assessed with chromium release assays.
RESULTS: Samples were collected from 37 patients with advanced ovarian cancer. FACS was performed on 27 ascites specimens. A low CD4/CD8 ratio (<1.6) was seen in 13 patient samples and associated with significantly improved overall survival (p=0.040). LINCOplex evaluation of 22 paired ascites and plasma samples demonstrated significantly elevated levels of IL-6, IL-8, IL-10, IL-15, IP-10, MCP-1, MIP-1beta and VEGF and significantly reduced levels of IL-2, IL-5, IL-7, IL-17, PDGF-BB, and RANTES in ascites compared to plasma (p<0.05). Autologous ovarian cancer cell lysis with T-lymphocytes from ascites was limited. Although aAPC stimulation resulted in effective expansion of antigen specific T-cells from peripheral lymphocytes (35-fold), only limited expansion was noted from ascites-derived lymphocytes (10-fold).
CONCLUSION: Ovarian cancer-associated ascites may provide an immunosuppressive environment. A high CD4/CD8 ratio, which may indicate the presence of regulatory T-cells, is associated with poor outcome. Reduced IL-2 and elevated IL-6 and IL-10 levels favor a Th2 inhibitory immune response. This immunosuppressive climate may explain our observation of non responsiveness in ascites derived T-cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19661290

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  83 in total

1.  Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients.

Authors:  Jessica Vazquez; Melina Chavarria; Gladys E Lopez; Mildred A Felder; Arvinder Kapur; Antonio Romo Chavez; Nathan Karst; Lisa Barroilhet; Manish S Patankar; Aleksandar K Stanic
Journal:  Am J Reprod Immunol       Date:  2020-06-30       Impact factor: 3.886

2.  Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.

Authors:  Molly J Carroll; Kaitlin C Fogg; Harin A Patel; Harris B Krause; Anne-Sophie Mancha; Manish S Patankar; Paul S Weisman; Lisa Barroilhet; Pamela K Kreeger
Journal:  Cancer Res       Date:  2018-05-08       Impact factor: 12.701

3.  Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population.

Authors:  Andrew J Gawron; Angela J Fought; Jolanta Lissowska; Weimin Ye; Xiao Zhang; Wong-Ho Chow; Laura E Beane Freeman; Lifang Hou
Journal:  Scand J Gastroenterol       Date:  2010-11-22       Impact factor: 2.423

Review 4.  The biological significance and clinical applications of exosomes in ovarian cancer.

Authors:  Kalpana Deepa Priya Dorayappan; John J Wallbillich; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2016-04-10       Impact factor: 5.482

5.  Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.

Authors:  Nonna Kolomeyevskaya; Kevin H Eng; Anm Nazmul H Khan; Kassondra S Grzankowski; Kelly L Singel; Kirsten Moysich; Brahm H Segal
Journal:  Gynecol Oncol       Date:  2015-05-20       Impact factor: 5.482

Review 6.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

Review 7.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

8.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

9.  Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Authors:  Peter C Hart; Preety Bajwa; Hilary A Kenny
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.